<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pers Med</journal-id><journal-id journal-id-type="iso-abbrev">J Pers Med</journal-id><journal-id journal-id-type="publisher-id">jpm</journal-id><journal-title-group><journal-title>Journal of Personalized Medicine</journal-title></journal-title-group><issn pub-type="epub">2075-4426</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39728064</article-id><article-id pub-id-type="pmc">PMC11680007</article-id>
<article-id pub-id-type="doi">10.3390/jpm14121151</article-id><article-id pub-id-type="publisher-id">jpm-14-01151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effects of Auto-Titrating Mandibular Advancement Device on Autonomic Nervous System in Obstructive Sleep Apnea</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5164-4274</contrib-id><name><surname>Son</surname><given-names>Dae-Soon</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-jpm-14-01151" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jae-In</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af2-jpm-14-01151" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Dong-Kyu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-jpm-14-01151" ref-type="aff">3</xref><xref rid="af4-jpm-14-01151" ref-type="aff">4</xref><xref rid="c1-jpm-14-01151" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Pritzker</surname><given-names>Kenneth P.H.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Rizzieri</surname><given-names>David Alan</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jpm-14-01151"><label>1</label>Department of Data Science and Data Science Convergence Research Center, Hallym University, Chuncheon 24252, Republic of Korea</aff><aff id="af2-jpm-14-01151"><label>2</label>Department of Physiology, Neurology, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea</aff><aff id="af3-jpm-14-01151"><label>3</label>Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea</aff><aff id="af4-jpm-14-01151"><label>4</label>Institute of New Frontier Research, Division of Big Data and Artificial Intelligence, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea</aff><author-notes><corresp id="c1-jpm-14-01151"><label>*</label>Correspondence: <email>entkim@hallym.or.kr</email>; Tel.: +82-33-240-5180</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>14</volume><issue>12</issue><elocation-id>1151</elocation-id><history><date date-type="received"><day>30</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>09</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> One prior study revealed that a newly developed auto-titrating mandibular advancement device (AMAD) could potentially enhance polysomnographic outcomes in individuals with obstructive sleep apnea (OSA). However, evidence regarding its impact on autonomic nervous system dysregulation in OSA remains limited. In this study, we aimed to compare the effects of conventional mandibular advancement devices (MADs) and AMDA on autonomic function. <bold>Methods</bold>: We retrospectively reviewed data from patients who visited a sleep center with complaints of snoring and sleep apnea (30 and 15 patients in the conventional MAD and AMAD groups, respectively). We assessed heart rate variability (HRV) frequency-domain metrics such as total power (TP), very low frequency (VLF), low frequency (LF), and high frequency (HF) using ultra-short-term and short-term modalities, assessing sympathetic and parasympathetic activity changes across treatment groups. <bold>Results</bold>: Conventional MAD treatment was associated with reductions in LF and LF/HF ratios, whereas AMAD treatment was linked to decreases in TP, VLF, LF, and LF/HF ratios. Notably, in patients with moderate OSA, LF values were significantly lower in the AMAD group than in the conventional MAD group. <bold>Conclusions</bold>: These findings suggest that both devices could reduce sympathetic over-activity in patients with OSA, with AMAD demonstrating greater efficacy, particularly in those with moderate OSA.</p></abstract><kwd-group><kwd>sleep</kwd><kwd>apnea</kwd><kwd>autonomic</kwd><kwd>mandibular advancement devices</kwd><kwd>orthodontic appliances</kwd></kwd-group><funding-group><award-group><funding-source>Hallym University Research Fund</funding-source><award-id>HURF-2024-10</award-id></award-group><funding-statement>This study was supported by a grant from the Hallym University Research Fund (HURF-2024-10).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-jpm-14-01151"><title>1. Introduction</title><p>Obstructive sleep apnea (OSA) is characterized by repeated upper airway obstruction, leading to intermittent hypoxia, fluctuations in intrathoracic pressure, and sleep disruption. The recurrent episodes of apnea and hypopnea during sleep trigger intermittent hypoxia, significant intrathoracic pressure fluctuations, and the activation of the sympathetic branch of the autonomic nervous system (ANS). The ANS, composed of sympathetic and parasympathetic branches, plays a critical role in regulating physiological states, particularly blood pressure. Consequently, dysregulated autonomic function, particularly increased sympathetic activity, is central to the development of hypertension [<xref rid="B1-jpm-14-01151" ref-type="bibr">1</xref>,<xref rid="B2-jpm-14-01151" ref-type="bibr">2</xref>,<xref rid="B3-jpm-14-01151" ref-type="bibr">3</xref>,<xref rid="B4-jpm-14-01151" ref-type="bibr">4</xref>]. OSA further affects blood pressure, as patients typically exhibit cyclical fluctuations in heart rate and blood pressure patterns. Such fluctuations are caused by a combination of chemoreflex-driven sympathetic activation and altered ventricular filling due to intrathoracic pressure shifts during OSA episodes. They are associated with heightened sympathetic activation and parasympathetic variability, contributing to the increased risk of hypertension and cardiovascular disease [<xref rid="B5-jpm-14-01151" ref-type="bibr">5</xref>,<xref rid="B6-jpm-14-01151" ref-type="bibr">6</xref>,<xref rid="B7-jpm-14-01151" ref-type="bibr">7</xref>,<xref rid="B8-jpm-14-01151" ref-type="bibr">8</xref>].</p><p>Managing OSA involves a multifaceted approach tailored to each patient. Continuous positive airway pressure (CPAP) remains the gold-standard treatment for moderate-to-severe OSA in adults [<xref rid="B9-jpm-14-01151" ref-type="bibr">9</xref>,<xref rid="B10-jpm-14-01151" ref-type="bibr">10</xref>]; however, its effectiveness is undermined by low adherence rates. To address this issue, a mandibular advancement device (MAD) was introduced as an alternative treatment modality and can be used as a first-line option for patients with simple snoring, mild-to-moderate OSA with low BMI, or increased upper airway resistance syndrome [<xref rid="B11-jpm-14-01151" ref-type="bibr">11</xref>]. MAD therapy has become popular because of its superior convenience and patient compliance [<xref rid="B11-jpm-14-01151" ref-type="bibr">11</xref>]. For instance, MADs offer specific advantages over CPAP, such as not requiring electricity and being more convenient to use in different sleep environments, making it a viable option for patients who do not improve with CPAP therapy or have poor adherence.</p><p>Conventional MAD works by protruding the mandible during sleep to maintain upper airway patency. Recently, OUaR LaB, Inc. (Seoul, Republic of Korea) developed a novel type of MAD called the auto-titrating mandibular advancement device (AMAD) system, which features an innovative mechanism that automatically adjusts the degree of mandibular advancement based on the patient&#x02019;s sleep position, increasing the degree when the patient is lying on their back and reducing it when they are on their side (<xref rid="jpm-14-01151-f001" ref-type="fig">Figure 1</xref>). This dynamic adjustment enhances its therapeutic efficacy for OSA and reduces the risk of side effects typically associated with static mandibular traction during sleep. A recent clinical trial indicated that AMAD may provide an effective alternative treatment for OSA, significantly improving various respiratory parameters, including the apnea&#x02013;hypopnea index (AHI), lowest oxygen saturation, and arousal index [<xref rid="B12-jpm-14-01151" ref-type="bibr">12</xref>]. Furthermore, no severe side effects such as hypersalivation, dental discomfort, mucosal dryness, or jaw pain were reported during the short-term application of AMAD. However, evidence to confirm improvements in ANS dysregulation with successful AMAD therapy for OSA remains insufficient. Heart rate variability (HRV) is known to reflect ANS balance and has implications for cardiovascular health [<xref rid="B13-jpm-14-01151" ref-type="bibr">13</xref>]. Additionally, night-time HRV could serve as a valuable metric for assessing the effectiveness of MAD in treating OSA [<xref rid="B14-jpm-14-01151" ref-type="bibr">14</xref>].</p><p>We proposed that conventional MAD and AMAD might have distinct effects on enhancing cardiac autonomic function in patients with OSA. Thus, this study aimed to evaluate and compare the impact of conventional MAD and AMAD therapies on autonomic nervous system function, measured through an HRV analysis.</p></sec><sec id="sec2-jpm-14-01151"><title>2. Materials and Methods</title><sec id="sec2dot1-jpm-14-01151"><title>2.1. Study Population</title><p>We retrospectively reviewed data from patients who visited a sleep center with complaints of snoring and sleep apnea. The inclusion criteria were as follows: (1) patients aged &#x02265;18 years; (2) patients diagnosed with mild-to-moderate OSA (AHI between 5 and 30 events per hour); (3) patients treated with either a conventional MAD (SomnoDent; SomnoMed Ltd., Crows Nest, NSW, Australia) or AMAD (Oxleep&#x02122;; OUaR LaB, Inc., Republic of Korea); and (4) patients who underwent follow-up polysomnography (PSG) 6 months after initiating treatment, with both baseline and post-MAD data available, and were identified as therapy responders. The exclusion criteria were (1) patients with a history of conditions known to affect HRV (e.g., cardiac arrhythmias, myocardial infarction, diabetic neuropathy, cardiac transplantation, myocardial dysfunction, tetraplegia); (2) patients with low-quality PSG raw data, such as artifacts affecting more than 20% of total sleep time; (3) patients with concurrent sleep disorders, such as insomnia or narcolepsy; (4) chronic users of sedatives or hypnotics; and (5) patients classified as non-responders to treatment.</p><p>Anthropometric data were collected for all participants, and their levels of daytime sleepiness and subjective sleep quality were assessed using standardized questionnaires: the Epworth Sleepiness Scale (ESS) for measuring daytime drowsiness and the Pittsburgh Sleep Quality Index (PSQI) for evaluating overall sleep quality. We also collected and compared baseline characteristics between the two groups, offering insights into the differences in patient characteristics and sleep metrics before treatment initiation. These baseline comparisons are crucial for understanding the initial conditions and validating subsequent evaluations of treatment effects. The study adhered to ethical standards outlined by the institutional research committee and complied with the 1964 Declaration of Helsinki and its subsequent amendments, ensuring the protection of participants&#x02019; rights and safety. Ethical approval was obtained from the Institutional Review Board (IRB) of Hallym University Chuncheon Sacred Hospital (IRB No. 2024-01-012, date: 12 January 2024). All data used in this study were fully included in the analysis. Additional data may be available for further review upon request, pending institutional approval and compliance with relevant data protection regulations.</p></sec><sec id="sec2dot2-jpm-14-01151"><title>2.2. Sleep Study</title><p>A standard overnight PSG was conducted at the Chuncheon Sacred Hospital sleep laboratory using a computerized system (Nox-A1; Nox Medical, Reykjavik, Iceland). Each participant underwent an 8 h overnight PSG monitoring session while in bed. Participants were instructed to avoid alcohol, caffeine, naps, and prolonged or intense physical activity on the day of the study. During PSG monitoring, we gathered physiological data such as electroencephalogram, electromyogram, electrooculogram, electrocardiogram, and oxygen saturation levels; body movements; and nasal airflow. We scored sleep stages and respiratory events according to the American Academy of Sleep Medicine guidelines [<xref rid="B15-jpm-14-01151" ref-type="bibr">15</xref>]. The sleep parameters assessed included the total sleep time (TST), sleep efficiency (TST divided by time in bed, expressed as a percentage), oxygen desaturation index (ODI), and AHI. ODI refers to the number of oxygen desaturation episodes per hour of sleep, with desaturation defined as &#x0003e;3% reduction in blood oxygen saturation from the baseline. Apnea was detected with an oronasal thermal sensor when the signal decreased by &#x02265;90% from the baseline for at least 10 s. Hypopnea was recorded when nasal pressure signal excursions decreased by &#x02265;30% from the baseline for at least 10 s, accompanied by a &#x02265;3% drop in oxygen saturation or arousal. AHI represents the combined total events of apneas and hypopneas per hour of sleep. OSA severity was classified based on AHI: no OSA (AHI &#x0003c; 5 per hour), mild OSA (AHI between 5 and 15 per hour), moderate OSA (AHI between 15 and 30 per hour), and severe OSA (AHI &#x02265; 30 per hour). Successful MAD treatment was defined as &#x0003e;50% reduction in AHI, with AHI dropping below 10 events per hour while using the MAD compared to the baseline value. Additionally, a treatment response was defined as &#x0003e;50% reduction in AHI, with AHI falling below 20 events per hour when using MAD compared to baseline values [<xref rid="B16-jpm-14-01151" ref-type="bibr">16</xref>]. Participants who did not achieve these thresholds were classified into the non-response group.</p></sec><sec id="sec2dot3-jpm-14-01151"><title>2.3. Assessment of Autonomic Function</title><p>HRV refers to fluctuations in the time interval between consecutive heartbeats, typically measured through RR intervals from an ECG signal. HRV represents the balance between the parasympathetic and sympathetic nervous systems. A nocturnal HRV analysis is widely used as a noninvasive assessment of autonomic function across various fields [<xref rid="B17-jpm-14-01151" ref-type="bibr">17</xref>]. Evidence also shows that HRV can evaluate changes in ANS activity and may be a valuable indicator of OSA severity [<xref rid="B18-jpm-14-01151" ref-type="bibr">18</xref>,<xref rid="B19-jpm-14-01151" ref-type="bibr">19</xref>,<xref rid="B20-jpm-14-01151" ref-type="bibr">20</xref>]. In this study, we extracted electrocardiography data from PSG recordings to ensure accuracy and quality through visual inspection. We removed ectopic beats and artifacts and included only normal-to-normal beats in the HRV analysis. Time-domain HRV parameters reflect the variability in beat-to-beat intervals, affecting sympathetic and parasympathetic nervous system activity. However, these parameters are generally not used to differentiate the balance between sympathetic and parasympathetic functions. Therefore, we focused on frequency-domain HRV parameters. We applied a spectral power analysis by shifting predetermined segments (ultra-short term of 2 min and short term of 5 min) forward by 2 s throughout the entire 10 min HRV dataset collected from each patient. The frequency-domain parameters were total power (TP), representing power at frequencies &#x02264; 0.4 Hz; very low frequency (VLF), at frequencies &#x02264; 0.04 Hz; low frequency (LF), between 0.04 and 0.15 Hz; and high frequency (HF), between 0.15 and 0.4 Hz. The LF/HF ratio was calculated by dividing the LF by the HF. Normalized LF power (LFnu) is expressed as [LF/(LF + HF) &#x000d7; 100], whereas normalized HF power (HFnu) is expressed as [HF/(LF + HF) &#x000d7; 100]. In the time-domain HRV analysis, short-term segments of HRV were generally measured over 5 min, with the magnitude of frequency components derived from the spectral analysis being valuable for evaluating ANS activity. However, the HRV analysis using short-term segments has inherent limitations in clinical practice, as its spectral estimates cannot capture rapid ANS fluctuations. Consequently, ultra-short-term segmentation (lasting less than 5 min) has recently been introduced across various medical disciplines, including sleep medicine [<xref rid="B19-jpm-14-01151" ref-type="bibr">19</xref>].</p></sec><sec id="sec2dot4-jpm-14-01151"><title>2.4. Statistical Analysis</title><p>Most variables collected in this study were continuous variables reported as the mean &#x000b1; standard deviation, with the exception of sex, which was a categorical variable represented as a ratio. To compare the baseline characteristics of each treatment group (conventional MAD and AMAD groups), we used independent <italic toggle="yes">t</italic> tests or chi-square tests. To assess the differences between baseline parameters and those after MAD treatment, a paired <italic toggle="yes">t</italic> test was used. Welch&#x02019;s <italic toggle="yes">t</italic> test was performed to compare HRV parameters between the conventional MAD and AMAD groups. All statistical analyses were performed using R software for Windows (version 4.0.0; R Foundation for Statistical Computing, Vienna, Austria). Based on the G power program, in the present study, the sample size was calculated based on an effect size of 0.7, a parent distribution assumed to follow a Laplace distribution, and an alpha error of 0.05. All <italic toggle="yes">p</italic> values were two-sided, with statistical significance at <italic toggle="yes">p</italic> &#x0003c; 0.05 in two-tailed tests.</p></sec></sec><sec sec-type="results" id="sec3-jpm-14-01151"><title>3. Results</title><sec id="sec3dot1-jpm-14-01151"><title>3.1. Patient Characteristics</title><p>Following the inclusion and exclusion criteria, 30 participants were allocated to the conventional MAD group and 15 to the AMAD group. Baseline demographic characteristics, clinical profiles, and overnight polysomnographic findings for all participants are shown in <xref rid="jpm-14-01151-t001" ref-type="table">Table 1</xref>. No statistically significant differences were found between the conventional MAD and AMAD groups in terms of baseline characteristics such as sex, age, body mass index, ESS, and PSQI. Similarly, no significant differences were observed between the two groups in baseline PSG parameters, including TST, sleep latency, sleep efficiency, AHI, and ODI.</p></sec><sec id="sec3dot2-jpm-14-01151"><title>3.2. Changes in Nocturnal Heart Rate Variability According to the Different Types of Mandibular Advancement Devices</title><p>Among patients receiving conventional MAD treatment, the LF value demonstrated significant reductions in ultra-short-term (15,052.29 &#x000b1; 1057.50) and short-term (15,061.61 &#x000b1; 1031.05) HRV analyses. Additionally, the short-term HRV analysis revealed a marked increase in VLF values (24,087.84 &#x000b1; 7524.17) in these patients (<xref rid="jpm-14-01151-t002" ref-type="table">Table 2</xref>). Similarly, in patients undergoing AMAD treatment, significant reductions were observed in TP, VLF, LF, and LF/HF ratios in both ultra-short-term (43,356.15 &#x000b1; 7398.55, 19,137.63 &#x000b1; 7398.55, 13,645.90 &#x000b1; 797.45, and 2.38 &#x000b1; 0.50) and short-term (41,268.15 &#x000b1; 6843.13, 22,638.98 &#x000b1; 4620.36, 14,090.57 &#x000b1; 709.80, and 2.59 &#x000b1; 0.59) HRV analyses. However, no significant changes were observed in HF values in patients treated with AMAD across both the ultra-short-term and short-term HRV assessments (<xref rid="jpm-14-01151-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot3-jpm-14-01151"><title>3.3. The Comparison of the Changes in Nocturnal Heart Rate Variability According to the Severity of Obstructive Sleep Apnea</title><p>In patients diagnosed with mild OSA, no statistically significant differences were identified in any of the HRV parameters when comparing the conventional MAD group to the AMAD group, as demonstrated in <xref rid="jpm-14-01151-t004" ref-type="table">Table 4</xref>. These findings suggest that both devices may exert similar effects on ANS function in this subgroup of patients with milder forms of OSA. However, a different trend was observed in patients with moderate OSA. In this group, LF levels were notably and significantly lower in the AMAD group than in the conventional MAD group. Specifically, the LF levels were 13,354.77 &#x000b1; 637.35 in the ultra-short term and 13,870.29 &#x000b1; 757.24 in the short term, as shown in <xref rid="jpm-14-01151-t005" ref-type="table">Table 5</xref>. This finding highlights the potential differences in the physiological impact between the two devices, particularly in patients with more pronounced disease severity.</p></sec></sec><sec sec-type="discussion" id="sec4-jpm-14-01151"><title>4. Discussion</title><p>Although the exact underlying mechanisms linking OSA and cardiovascular complications remain poorly understood, it is well established that patients with OSA often exhibit increased sympathetic nervous system activity and alterations in ANS function. These changes in the ANS may contribute to the cardiovascular risks associated with OSA. While various treatments have been explored for their impact on ANS function, it is important to note that the specific effects of AMAD therapy on ANS dysregulation have not yet been thoroughly investigated. Therefore, in this study, we sought to explore the differential effects of conventional MAD and AMAD therapies on ANS function by utilizing HRV measurements as an indicator of ANS activity. Additionally, we used ultra-short-term HRV features, which have been increasingly applied across various medical fields to address the limitations of short-term HRV measures [<xref rid="B19-jpm-14-01151" ref-type="bibr">19</xref>,<xref rid="B21-jpm-14-01151" ref-type="bibr">21</xref>,<xref rid="B22-jpm-14-01151" ref-type="bibr">22</xref>,<xref rid="B23-jpm-14-01151" ref-type="bibr">23</xref>], to assess ANS function in patients with OSA along with short-term HRV features. Our findings showed that MAD therapy significantly altered cardiac autonomic modulation, as reflected by nocturnal HRV, with more pronounced changes in patients with moderate OSA treated with AMAD compared to those treated with conventional MAD.</p><p>OSA is a common sleep-breathing disorder associated with disturbances in the ANS function. PSG parameters and sleep questionnaires are widely recognized as classical and representative methods for evaluating the efficacy of treatments for OSA. These tools are valuable in assessing various aspects of sleep quality and treatment effectiveness. However, despite their usefulness, they are limited in their ability to provide insights into ANS function. While PSG and sleep questionnaires measure sleep architecture and subjective experiences, they do not capture the complex physiological changes associated with ANS regulation, which is critical in understanding the broader impact of OSA treatments on cardiovascular and autonomic health. Therefore, additional evaluation methods, such as HRV measurements, are necessary to assess ANS function in this context.</p><p>HRV serves as a crucial noninvasive marker for assessing autonomic regulation. HRV is usually described by frequency-domain measurements, such as HF and LF. The HF components of HRV indicate parasympathetic activity, whereas the LF components reflect sympathetic activity [<xref rid="B18-jpm-14-01151" ref-type="bibr">18</xref>]. Several studies have confirmed that patients with OSA exhibit increased sympathetic activity and reduced parasympathetic function. Typically, sympathetic activity decreases, and parasympathetic activity increases during sleep. However, in patients with OSA, ANS alterations, particularly sympathetic over-activity, occur both acutely during apnea events and chronically during the daytime. These disruptions contribute to the cardiovascular consequences of sleep-disordered breathing. In healthy controls, the ANS functions in a well-coordinated manner during sleep; however, in patients with OSA, sympathetic nerve impairment results in an incomplete suppression of sympathetic activity, which is typically inhibited during sleep. Respiratory events may also trigger abnormal sympathetic activation, contributing to an abnormal elevation in the LF values. Consequently, the LF frequency-domain index may be a more sensitive marker for detecting sympathetic nerve impairments during sleep in patients with OSA.</p><p>A recent meta-analysis revealed that patients with OSA exhibited significantly elevated LF power and an increased LF/HF ratio during nocturnal periods, indicating reduced parasympathetic activity [<xref rid="B24-jpm-14-01151" ref-type="bibr">24</xref>]. Additionally, the LF/HF ratio demonstrates significant robustness in patients with OSA, suggesting its potential as a valuable tool in the future diagnosis of the condition [<xref rid="B24-jpm-14-01151" ref-type="bibr">24</xref>]. Moreover, the relationship between OSA and sympathetic dysregulation appears to be dose-dependent, with evidence suggesting that sympathetic over-activity may be reversible upon the initiation of OSA treatment [<xref rid="B2-jpm-14-01151" ref-type="bibr">2</xref>,<xref rid="B3-jpm-14-01151" ref-type="bibr">3</xref>]. Consistent with these findings, our study revealed a prominent improvement in LF values in patients with moderate OSA treated with AMAD compared to those treated with conventional MAD. Previous studies also show that age, sex, and BMI can significantly influence HRV in healthy individuals. However, in this study, no significant differences in these variables were observed between the conventional MAD and AMAD groups [<xref rid="B25-jpm-14-01151" ref-type="bibr">25</xref>,<xref rid="B26-jpm-14-01151" ref-type="bibr">26</xref>,<xref rid="B27-jpm-14-01151" ref-type="bibr">27</xref>].</p><p>This study has some limitations. First, we acknowledge the small sample size as a limitation of our study. Because this was a pilot study evaluating a new medical device, ethical considerations limited the inclusion of a larger cohort. Future studies with larger and more diverse populations are needed to confirm our findings. Second, unfortunately, due to the retrospective nature of the data and our focus on comparing two active treatments, we did not include a control group in this study. Furthermore, our IRB does not ethically permit the use of a placebo treatment with no proven medical efficacy as a control group for patients who visit for treatment purposes. We believe that this is a fundamental limitation of medical device research in general. Therefore, to overcome this limitation, we included a group of patients using a conventional MAD instead of a control group in this study. Third, the presence of comorbidities may have influenced the inflammatory state in patients with OSA, potentially acting as a confounding factor in the HRV analysis [<xref rid="B28-jpm-14-01151" ref-type="bibr">28</xref>,<xref rid="B29-jpm-14-01151" ref-type="bibr">29</xref>,<xref rid="B30-jpm-14-01151" ref-type="bibr">30</xref>,<xref rid="B31-jpm-14-01151" ref-type="bibr">31</xref>]. Fourth, only time-domain HRV parameters were evaluated to assess ANS function, as frequency-domain HRV parameters require longer RR interval segments for an accurate analysis. Fifth, although we matched the major independent variables, including sex, age, and BMI, between the two groups, our study did not include HRV data from control subjects, limiting comparative insights. Sixth, we relied solely on linear methods for HRV feature extraction without incorporating non-linear approaches. Future studies should compare linear and non-linear methodologies. Lastly, further investigation is needed to assess the long-term effects of MAD treatment in patients with OSA.</p></sec><sec sec-type="conclusions" id="sec5-jpm-14-01151"><title>5. Conclusions</title><p>Considering that the effects of AMAD on ANS dysregulation have not been studied, in this study, we examined the differential effects of conventional MAD and AMAD therapies on ANS function using HRV measurements. By examining these differences, we wanted to provide valuable insights into how these therapeutic approaches may influence ANS regulation and, consequently, cardiovascular health in patients with OSA. Notably, we found that MAD use alters cardiac autonomic modulation, particularly by reducing sympathetic activity. Moreover, AMAD had a more pronounced effect in lowering sympathetic parameters compared to conventional MAD in patients with moderate OSA. This effect was not observed in patients with mild OSA, suggesting a potential association between MAD treatment and the reduction in cardiac autonomic dysregulation, which may help reduce cardiovascular risk. Additionally, the use of AMAD could provide enhanced patient outcomes compared to conventional MAD, paving the way for more personalized treatment approaches.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.-S.S. and D.-K.K.; Methodology, D.-S.S. and J.-I.K.; Software, D.-S.S.; Validation, D.-K.K.; Data Curation, D.-S.S. and J.-I.K.; Writing&#x02014;Original Draft Preparation, D.-S.S., J.-I.K. and D.-K.K.; Writing&#x02014;Review and Editing, D.-S.S., J.-I.K. and D.-K.K.; Visualization, D.-K.K.; Supervision, D.-K.K.; Project Administration, D.-S.S. and D.-K.K.; Funding Acquisition, D.-K.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was approved by the Institutional Review Board (IRB) of Hallym University Chuncheon Sacred Hospital (IRB No. 2024-01-012, date: 12 January 2024).</p></notes><notes><title>Informed Consent Statement</title><p>As the dataset consisted of de-identified secondary data, the requirement for obtaining written informed consent was waived by the IRB.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All pertinent data supporting the conclusions of this study are provided in the analysis. Additional data may be requested for further review with access contingent on institutional approval and data protection guidelines.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-jpm-14-01151"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>W.</given-names></name>
<name><surname>Nagubadi</surname><given-names>S.</given-names></name>
<name><surname>Kryger</surname><given-names>M.H.</given-names></name>
<name><surname>Mokhlesi</surname><given-names>B.</given-names></name>
</person-group><article-title>Epidemiology of Obstructive Sleep Apnea: A Population-based Perspective</article-title><source>Expert Rev. Respir. Med.</source><year>2008</year><volume>2</volume><fpage>349</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1586/17476348.2.3.349</pub-id><pub-id pub-id-type="pmid">19690624</pub-id>
</element-citation></ref><ref id="B2-jpm-14-01151"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lombardi</surname><given-names>C.</given-names></name>
<name><surname>Pengo</surname><given-names>M.F.</given-names></name>
<name><surname>Parati</surname><given-names>G.</given-names></name>
</person-group><article-title>Pengo. Obstructive sleep apnea syndrome and autonomic dysfunction</article-title><source>Auton. Neurosci.</source><year>2019</year><volume>221</volume><fpage>102563</fpage><pub-id pub-id-type="doi">10.1016/j.autneu.2019.102563</pub-id><pub-id pub-id-type="pmid">31445406</pub-id>
</element-citation></ref><ref id="B3-jpm-14-01151"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ito</surname><given-names>R.</given-names></name>
<name><surname>Hamada</surname><given-names>H.</given-names></name>
<name><surname>Yokoyama</surname><given-names>A.</given-names></name>
<name><surname>Oshima</surname><given-names>M.</given-names></name>
<name><surname>Katayama</surname><given-names>H.</given-names></name>
<name><surname>Ohnishi</surname><given-names>H.</given-names></name>
<name><surname>Kadowaki</surname><given-names>T.</given-names></name>
<name><surname>Ishimaru</surname><given-names>S.</given-names></name>
<name><surname>Irifune</surname><given-names>K.</given-names></name>
<name><surname>Higaki</surname><given-names>J.</given-names></name>
</person-group><article-title>Successful treatment of obstructive sleep apnea syndrome improves autonomic nervous system dysfunction</article-title><source>Clin. Exp. Hypertens.</source><year>2005</year><volume>27</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1081/CEH-48874</pub-id><pub-id pub-id-type="pmid">15835389</pub-id>
</element-citation></ref><ref id="B4-jpm-14-01151"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ucak</surname><given-names>S.</given-names></name>
<name><surname>Dissanayake</surname><given-names>H.U.</given-names></name>
<name><surname>de Chazal</surname><given-names>P.</given-names></name>
<name><surname>Bin</surname><given-names>Y.S.</given-names></name>
<name><surname>Sutherland</surname><given-names>K.</given-names></name>
<name><surname>Setionago</surname><given-names>B.</given-names></name>
<name><surname>Tong</surname><given-names>B.</given-names></name>
<name><surname>Yee</surname><given-names>B.J.</given-names></name>
<name><surname>Kairaitis</surname><given-names>K.</given-names></name>
<name><surname>Wheatley</surname><given-names>J.R.</given-names></name>
<etal/>
</person-group><article-title>Heart rate variability analysis in obstructive sleep apnea patients with daytime sleepiness</article-title><source>Sleep</source><year>2024</year><volume>47</volume><fpage>zsae075</fpage><pub-id pub-id-type="doi">10.1093/sleep/zsae075</pub-id><pub-id pub-id-type="pmid">38531670</pub-id>
</element-citation></ref><ref id="B5-jpm-14-01151"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yacoub</surname><given-names>M.</given-names></name>
<name><surname>Youssef</surname><given-names>I.</given-names></name>
<name><surname>Salifu</surname><given-names>M.O.</given-names></name>
<name><surname>McFarlane</surname><given-names>S.I.</given-names></name>
</person-group><article-title>Cardiovascular Disease Risk in Obstructive Sleep apnea: An Update</article-title><source>J Sleep Disord. Ther.</source><year>2017</year><volume>7</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.4172/2167-0277.1000283</pub-id><pub-id pub-id-type="pmid">29644149</pub-id>
</element-citation></ref><ref id="B6-jpm-14-01151"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kendzerska</surname><given-names>T.</given-names></name>
<name><surname>Leung</surname><given-names>R.S.</given-names></name>
<name><surname>Atzema</surname><given-names>C.L.</given-names></name>
<name><surname>Chandy</surname><given-names>G.</given-names></name>
<name><surname>Meteb</surname><given-names>M.</given-names></name>
<name><surname>Malhotra</surname><given-names>A.</given-names></name>
<name><surname>Hawker</surname><given-names>G.A.</given-names></name>
<name><surname>Gershon</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Cardiovascular consequences of obstructive sleep apnea in women: A historical cohort study</article-title><source>Sleep Med.</source><year>2020</year><volume>68</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2019.08.021</pub-id><pub-id pub-id-type="pmid">32028229</pub-id>
</element-citation></ref><ref id="B7-jpm-14-01151"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dredla</surname><given-names>B.K.</given-names></name>
<name><surname>Castillo</surname><given-names>P.R.</given-names></name>
</person-group><article-title>Cardiovascular consequences of obstructive sleep apnea</article-title><source>Curr Cardiol. Rep.</source><year>2019</year><volume>21</volume><fpage>137</fpage><pub-id pub-id-type="doi">10.1007/s11886-019-1228-3</pub-id><pub-id pub-id-type="pmid">31707504</pub-id>
</element-citation></ref><ref id="B8-jpm-14-01151"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwarz</surname><given-names>E.I.</given-names></name>
</person-group><article-title>Cardiovascular consequences of obstructive sleep apnea in different study models and novel perspectives</article-title><source>Curr. Opin. Pulm. Med.</source><year>2019</year><volume>25</volume><fpage>614</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1097/MCP.0000000000000618</pub-id><pub-id pub-id-type="pmid">31433310</pub-id>
</element-citation></ref><ref id="B9-jpm-14-01151"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>X.</given-names></name>
<name><surname>Pan</surname><given-names>L.</given-names></name>
<name><surname>Ren</surname><given-names>D.</given-names></name>
<name><surname>Du</surname><given-names>C.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
</person-group><article-title>Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: A meta-analysis</article-title><source>Sleep Med.</source><year>2013</year><volume>14</volume><fpage>1139</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2013.07.006</pub-id><pub-id pub-id-type="pmid">24054505</pub-id>
</element-citation></ref><ref id="B10-jpm-14-01151"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patil</surname><given-names>S.P.</given-names></name>
<name><surname>Ayappa</surname><given-names>I.A.</given-names></name>
<name><surname>Caples</surname><given-names>S.M.</given-names></name>
<name><surname>Kimoff</surname><given-names>R.J.</given-names></name>
<name><surname>Patel</surname><given-names>S.R.</given-names></name>
<name><surname>Harrod</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Treatment of adult obstructive sleep apnea with positive airway pressure: An American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment</article-title><source>J. Clin. Sleep Med.</source><year>2019</year><volume>15</volume><fpage>301</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.5664/jcsm.7638</pub-id><pub-id pub-id-type="pmid">30736888</pub-id>
</element-citation></ref><ref id="B11-jpm-14-01151"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramar</surname><given-names>K.</given-names></name>
<name><surname>Dort</surname><given-names>L.C.</given-names></name>
<name><surname>Katz</surname><given-names>S.G.</given-names></name>
<name><surname>Lettieri</surname><given-names>C.J.</given-names></name>
<name><surname>Harrod</surname><given-names>C.G.</given-names></name>
<name><surname>Thomas</surname><given-names>S.M.</given-names></name>
<name><surname>Chervin</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: An update for 2015</article-title><source>J. Clin. Sleep Med.</source><year>2015</year><volume>11</volume><fpage>773</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.5664/jcsm.4858</pub-id><pub-id pub-id-type="pmid">26094920</pub-id>
</element-citation></ref><ref id="B12-jpm-14-01151"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>On</surname><given-names>S.W.</given-names></name>
<name><surname>Kim</surname><given-names>D.K.</given-names></name>
<name><surname>Lee</surname><given-names>M.H.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>K.C.</given-names></name>
<name><surname>Byun</surname><given-names>S.H.</given-names></name>
<name><surname>Hong</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Clinical efficacy study of position-responding mandibular advancement device in patients with obstructive sleep apnea</article-title><source>Clin. Exp. Otorhinolaryngol.</source><year>2024</year><volume>17</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.21053/ceo.2024.00124</pub-id><pub-id pub-id-type="pmid">39206563</pub-id>
</element-citation></ref><ref id="B13-jpm-14-01151"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malik</surname><given-names>M.</given-names></name>
<name><surname>Bigger</surname><given-names>J.T.</given-names></name>
<name><surname>Camm</surname><given-names>A.J.</given-names></name>
<name><surname>Kleiger</surname><given-names>R.E.</given-names></name>
<name><surname>Malliani</surname><given-names>A.</given-names></name>
<name><surname>Moss</surname><given-names>A.J.</given-names></name>
<name><surname>Schwartz</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology</article-title><source>Eur. Heart J.</source><year>1996</year><volume>17</volume><fpage>354</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.eurheartj.a014868</pub-id><pub-id pub-id-type="pmid">8737210</pub-id>
</element-citation></ref><ref id="B14-jpm-14-01151"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.W.</given-names></name>
<name><surname>Kwon</surname><given-names>S.O.</given-names></name>
<name><surname>Lee</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Nocturnal heart rate variability may be useful for determining the efficacy of mandibular advancement devices for obstructive sleep apnea</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>1030</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-57780-7</pub-id><pub-id pub-id-type="pmid">31974381</pub-id>
</element-citation></ref><ref id="B15-jpm-14-01151"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berry</surname><given-names>R.B.</given-names></name>
<name><surname>Budhiraja</surname><given-names>R.</given-names></name>
<name><surname>Gottlieb</surname><given-names>D.J.</given-names></name>
<name><surname>Gozal</surname><given-names>D.</given-names></name>
<name><surname>Iber</surname><given-names>C.</given-names></name>
<name><surname>Kapur</surname><given-names>V.K.</given-names></name>
<name><surname>Marcus</surname><given-names>C.L.</given-names></name>
<name><surname>Mehra</surname><given-names>R.</given-names></name>
<name><surname>Parthasarathy</surname><given-names>S.</given-names></name>
<name><surname>Quan</surname><given-names>S.F.</given-names></name>
<etal/>
</person-group><article-title>Rules for scoring respiratory events in sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine</article-title><source>J. Clin. Sleep Med.</source><year>2012</year><volume>8</volume><fpage>597</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.5664/jcsm.2172</pub-id><pub-id pub-id-type="pmid">23066376</pub-id>
</element-citation></ref><ref id="B16-jpm-14-01151"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sher</surname><given-names>A.E.</given-names></name>
<name><surname>Schechtman</surname><given-names>K.B.</given-names></name>
<name><surname>Piccirillo</surname><given-names>J.F.</given-names></name>
</person-group><article-title>The efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndrome</article-title><source>Sleep</source><year>1996</year><volume>19</volume><fpage>156</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1093/sleep/19.2.156</pub-id><pub-id pub-id-type="pmid">8855039</pub-id>
</element-citation></ref><ref id="B17-jpm-14-01151"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajendra Acharya</surname><given-names>U.</given-names></name>
<name><surname>Paul Joseph</surname><given-names>K.</given-names></name>
<name><surname>Kannathal</surname><given-names>N.</given-names></name>
<name><surname>Lim</surname><given-names>C.M.</given-names></name>
<name><surname>Suri</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Heart rate variability: A review</article-title><source>Med. Biol. Eng. Comput.</source><year>2006</year><volume>44</volume><fpage>1031</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1007/s11517-006-0119-0</pub-id><pub-id pub-id-type="pmid">17111118</pub-id>
</element-citation></ref><ref id="B18-jpm-14-01151"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>H.</given-names></name>
<name><surname>Keenan</surname><given-names>B.T.</given-names></name>
<name><surname>Mazzotti</surname><given-names>D.R.</given-names></name>
<name><surname>Vaquerizo-Villar</surname><given-names>F.</given-names></name>
<name><surname>Kraemer</surname><given-names>J.F.</given-names></name>
<name><surname>Wessel</surname><given-names>N.</given-names></name>
<name><surname>Tufik</surname><given-names>S.</given-names></name>
<name><surname>Bittencourt</surname><given-names>L.</given-names></name>
<name><surname>Cistulli</surname><given-names>P.A.</given-names></name>
<name><surname>de Chazal</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Heart rate variability during wakefulness as a marker of obstructive sleep apnea severity</article-title><source>Sleep</source><year>2021</year><volume>44</volume><fpage>zsab018</fpage><pub-id pub-id-type="doi">10.1093/sleep/zsab018</pub-id><pub-id pub-id-type="pmid">33506267</pub-id>
</element-citation></ref><ref id="B19-jpm-14-01151"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ha</surname><given-names>S.S.</given-names></name>
<name><surname>Kim</surname><given-names>D.K.</given-names></name>
</person-group><article-title>Diagnostic efficacy of ultra-short term HRV analysis in obstructive sleep apnea</article-title><source>J. Pers. Med.</source><year>2022</year><volume>12</volume><elocation-id>1494</elocation-id><pub-id pub-id-type="doi">10.3390/jpm12091494</pub-id><pub-id pub-id-type="pmid">36143279</pub-id>
</element-citation></ref><ref id="B20-jpm-14-01151"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ucak</surname><given-names>S.</given-names></name>
<name><surname>Dissanayake</surname><given-names>H.U.</given-names></name>
<name><surname>Sutherland</surname><given-names>K.</given-names></name>
<name><surname>de Chazal</surname><given-names>P.</given-names></name>
<name><surname>Cistulli</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Heart rate variability and obstructive sleep apnea: Current perspectives and novel technologies</article-title><source>J. Sleep Res.</source><year>2021</year><volume>30</volume><fpage>e13274</fpage><pub-id pub-id-type="doi">10.1111/jsr.13274</pub-id><pub-id pub-id-type="pmid">33462936</pub-id>
</element-citation></ref><ref id="B21-jpm-14-01151"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Hwang</surname><given-names>H.B.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Ha</surname><given-names>J.H.</given-names></name>
<name><surname>Jang</surname><given-names>Y.</given-names></name>
<name><surname>Hwang</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>H.K.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>I.Y.</given-names></name>
</person-group><article-title>Mental stress assessment using ultra short term HRV analysis based on non-linear method</article-title><source>Biosensors</source><year>2022</year><volume>12</volume><elocation-id>465</elocation-id><pub-id pub-id-type="doi">10.3390/bios12070465</pub-id><pub-id pub-id-type="pmid">35884267</pub-id>
</element-citation></ref><ref id="B22-jpm-14-01151"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moya-Ramon</surname><given-names>M.</given-names></name>
<name><surname>Mateo-March</surname><given-names>M.</given-names></name>
<name><surname>Pe&#x000f1;a-Gonz&#x000e1;lez</surname><given-names>I.</given-names></name>
<name><surname>Zabala</surname><given-names>M.</given-names></name>
<name><surname>Javaloyes</surname><given-names>A.</given-names></name>
</person-group><article-title>Validity and reliability of different smartphones applications to measure HRV during short and ultra-short measurements in elite athletes</article-title><source>Comput. Methods Programs Biomed.</source><year>2022</year><volume>217</volume><elocation-id>106696</elocation-id><pub-id pub-id-type="doi">10.1016/j.cmpb.2022.106696</pub-id><pub-id pub-id-type="pmid">35172251</pub-id>
</element-citation></ref><ref id="B23-jpm-14-01151"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hietakoste</surname><given-names>S.</given-names></name>
<name><surname>Korkalainen</surname><given-names>H.</given-names></name>
<name><surname>Kainulainen</surname><given-names>S.</given-names></name>
<name><surname>Sillanm&#x000e4;ki</surname><given-names>S.</given-names></name>
<name><surname>Nikkonen</surname><given-names>S.</given-names></name>
<name><surname>Myllymaa</surname><given-names>S.</given-names></name>
<name><surname>Duce</surname><given-names>B.</given-names></name>
<name><surname>T&#x000f6;yr&#x000e4;s</surname><given-names>J.</given-names></name>
<name><surname>Lepp&#x000e4;nen</surname><given-names>T.</given-names></name>
</person-group><article-title>Longer apneas and hypopneas are associated with greater ultra-short-term HRV in obstructive sleep apnea</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>21556</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-77780-x</pub-id><pub-id pub-id-type="pmid">33298982</pub-id>
</element-citation></ref><ref id="B24-jpm-14-01151"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>F.</given-names></name>
<name><surname>Xiao</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Yi</surname><given-names>Y.</given-names></name>
<name><surname>Min</surname><given-names>W.</given-names></name>
<name><surname>Su</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Heart rate variability changes in patients with obstructive sleep apnea: A systematic review and meta-analysis</article-title><source>J. Sleep Res.</source><year>2023</year><volume>32</volume><fpage>e13708</fpage><pub-id pub-id-type="doi">10.1111/jsr.13708</pub-id><pub-id pub-id-type="pmid">36070876</pub-id>
</element-citation></ref><ref id="B25-jpm-14-01151"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garavaglia</surname><given-names>L.</given-names></name>
<name><surname>Gulich</surname><given-names>D.</given-names></name>
<name><surname>Defeo</surname><given-names>M.M.</given-names></name>
<name><surname>Thomas Mailland</surname><given-names>J.</given-names></name>
<name><surname>Irurzun</surname><given-names>I.M.</given-names></name>
</person-group><article-title>The effect of age on the heart rate variability of healthy subjects</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0255894</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0255894</pub-id><pub-id pub-id-type="pmid">34624048</pub-id>
</element-citation></ref><ref id="B26-jpm-14-01151"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>W.L.</given-names></name>
<name><surname>Chang</surname><given-names>L.R.</given-names></name>
<name><surname>Kuo</surname><given-names>T.B.J.</given-names></name>
<name><surname>Lin</surname><given-names>Y.H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.Z.</given-names></name>
<name><surname>Yang</surname><given-names>C.C.H.</given-names></name>
</person-group><article-title>Gender differences in personality and heart-rate variability</article-title><source>Psychiatry Res.</source><year>2013</year><volume>209</volume><fpage>652</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2013.01.031</pub-id><pub-id pub-id-type="pmid">23499230</pub-id>
</element-citation></ref><ref id="B27-jpm-14-01151"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gulgun</surname><given-names>M.</given-names></name>
<name><surname>Fidanci</surname><given-names>K.M.</given-names></name>
<name><surname>Genc</surname><given-names>F.A.</given-names></name>
</person-group><article-title>Body weight, BMI and insulin resistance as influential factors on heart rate variability</article-title><source>Respirology</source><year>2015</year><volume>20</volume><fpage>846</fpage><pub-id pub-id-type="doi">10.1111/resp.12562</pub-id></element-citation></ref><ref id="B28-jpm-14-01151"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>D.K.</given-names></name>
<name><surname>Lee</surname><given-names>B.C.</given-names></name>
<name><surname>Park</surname><given-names>K.J.</given-names></name>
<name><surname>Son</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Effect of obstructive sleep apnea on immunity in cases of chronic rhinosinusitis with nasal polyps</article-title><source>Clin. Exp. Otorhinolaryngol.</source><year>2021</year><volume>14</volume><fpage>390</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.21053/ceo.2020.02250</pub-id><pub-id pub-id-type="pmid">33541034</pub-id>
</element-citation></ref><ref id="B29-jpm-14-01151"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Ouyang</surname><given-names>R.</given-names></name>
<name><surname>Zeng</surname><given-names>Z.</given-names></name>
<name><surname>Zhan</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Cui</surname><given-names>Y.</given-names></name>
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Luo</surname><given-names>L.</given-names></name>
<name><surname>He</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>The relationship between inflammation and neurocognitive dysfunction in obstructive sleep apnea syndrome</article-title><source>J. Neuroinflamm.</source><year>2020</year><volume>17</volume><fpage>229</fpage><pub-id pub-id-type="doi">10.1186/s12974-020-01905-2</pub-id></element-citation></ref><ref id="B30-jpm-14-01151"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orr&#x000f9;</surname><given-names>G.</given-names></name>
<name><surname>Storari</surname><given-names>M.</given-names></name>
<name><surname>Scano</surname><given-names>A.</given-names></name>
<name><surname>Piras</surname><given-names>V.</given-names></name>
<name><surname>Taibi</surname><given-names>R.</given-names></name>
<name><surname>Viscuso</surname><given-names>D.</given-names></name>
</person-group><article-title>Obstructive Sleep Apnea, oxidative stress, inflammation and endothelial dysfunction-An overview of predictive laboratory biomarkers</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2020</year><volume>24</volume><fpage>6939</fpage><lpage>6948</lpage><pub-id pub-id-type="doi">10.26355/eurrev_202006_21685</pub-id><pub-id pub-id-type="pmid">32633387</pub-id>
</element-citation></ref><ref id="B31-jpm-14-01151"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>Q.</given-names></name>
<name><surname>Bian</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>S.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
<name><surname>Tong</surname><given-names>J.</given-names></name>
</person-group><article-title>Chronic intermittent hypoxia induces cardiac inflammation and dysfunction in a rat obstructive sleep apnea model</article-title><source>J. Biomed. Res.</source><year>2016</year><volume>30</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.7555/JBR.30.20160110</pub-id><pub-id pub-id-type="pmid">27924067</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="jpm-14-01151-f001"><label>Figure 1</label><caption><p>The design and structure of the auto-titrating mandibular advancement device.</p></caption><graphic xlink:href="jpm-14-01151-g001" position="float"/></fig><table-wrap position="float" id="jpm-14-01151-t001"><object-id pub-id-type="pii">jpm-14-01151-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics and laboratory overnight polysomnographic parameters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conventional MAD (n = 30)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AMAD (n = 15)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sex (male, %)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (86.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (80.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">53.9 &#x000b1; 7.65</td><td align="center" valign="middle" rowspan="1" colspan="1">55.07 &#x000b1; 10.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">24.77 &#x000b1; 1.85</td><td align="center" valign="middle" rowspan="1" colspan="1">24.13 &#x000b1; 2.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.44</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ESS</td><td align="center" valign="middle" rowspan="1" colspan="1">6.57 &#x000b1; 2.25</td><td align="center" valign="middle" rowspan="1" colspan="1">6.27 &#x000b1; 1.39</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PSQI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.10 &#x000b1; 2.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.13 &#x000b1; 2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Baseline PSG</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total sleep time (min)</td><td align="center" valign="middle" rowspan="1" colspan="1">361.17 &#x000b1; 58.01</td><td align="center" valign="middle" rowspan="1" colspan="1">343.13 &#x000b1; 60.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.21</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sleep latency (min)</td><td align="center" valign="middle" rowspan="1" colspan="1">44.43 &#x000b1; 8.15</td><td align="center" valign="middle" rowspan="1" colspan="1">42.73 &#x000b1; 12.30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sleep efficiency (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">80.40 &#x000b1; 6.68</td><td align="center" valign="middle" rowspan="1" colspan="1">74.93 &#x000b1; 6.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AHI</td><td align="center" valign="middle" rowspan="1" colspan="1">14.77 &#x000b1; 9.13</td><td align="center" valign="middle" rowspan="1" colspan="1">14.13 &#x000b1; 6.23</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.57 &#x000b1; 5.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.93 &#x000b1; 5.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; standard deviation. AHI, apnea&#x02013;hypopnea index; AMAD, auto-titrating mandibular advancement device; BMI, body mass index; ESS, Epworth Sleepiness Scale; ODI, oxygen desaturation index; PSG, polysomnography; PSQI, Pittsburgh Sleep Quality Index.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jpm-14-01151-t002"><object-id pub-id-type="pii">jpm-14-01151-t002_Table 2</object-id><label>Table 2</label><caption><p>Efficacy of conventional mandibular advancement device (MAD) treatment on shift in autonomic dysregulation in patients with obstructive sleep apnea.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n = 30</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Baseline</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conventional MAD Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Ultra-short-term</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TP (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">71,417.84 &#x000b1; 91,198.39</td><td align="center" valign="middle" rowspan="1" colspan="1">44,059.44 &#x000b1; 8304.53</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4219 (0.1006, 0.9444)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VLF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">31,665.46 &#x000b1; 8280.15</td><td align="center" valign="middle" rowspan="1" colspan="1">24,407.97 &#x000b1; 20,520.27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4638 (&#x02212;0.0599, 0.9876)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">17,018.89 &#x000b1; 386.35</td><td align="center" valign="middle" rowspan="1" colspan="1">15,052.29 &#x000b1; 1057.50</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4703 (1.784, 3.1565)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">5836.69 &#x000b1; 1332.13</td><td align="center" valign="middle" rowspan="1" colspan="1">5942.05 &#x000b1; 1220.21</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0825 (&#x02212;0.5995, 0.4346)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF/HF ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">3.07 &#x000b1; 0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">2.63 &#x000b1; 0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6984 (0.1160, 1.2307)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LFnu</td><td align="center" valign="middle" rowspan="1" colspan="1">74.73 &#x000b1; 4.14</td><td align="center" valign="middle" rowspan="1" colspan="1">71.92 &#x000b1; 3.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7010 (0.1685, 1.2335)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HFnu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.27 &#x000b1; 4.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.08 &#x000b1; 3.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.7010 (&#x02212;1.2335, &#x02212;0.1685)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Short-term</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TP (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">67,694.21 &#x000b1; 65,636.94</td><td align="center" valign="middle" rowspan="1" colspan="1">42,875.24 &#x000b1; 8304.53</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5305 (0.0047, 1.0564)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VLF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">31,052.73 &#x000b1; 11,032.64</td><td align="center" valign="middle" rowspan="1" colspan="1">24,087.84 &#x000b1; 7524.17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7376 (0.2035, 1.2717)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">16,984.13 &#x000b1; 564.34</td><td align="center" valign="middle" rowspan="1" colspan="1">15,061.61 &#x000b1; 1031.05</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1332 (1.6455, 2.9808)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">5740.93 &#x000b1; 1516.62</td><td align="center" valign="middle" rowspan="1" colspan="1">5565.60 &#x000b1; 1256.20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1259 (&#x02212;0.3914, 0.6433)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF/HF ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">3.17 &#x000b1; 0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">2.83 &#x000b1; 0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4738 (&#x02212;0.0502, 0.9979)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LFnu</td><td align="center" valign="middle" rowspan="1" colspan="1">75.09 &#x000b1; 4.74</td><td align="center" valign="middle" rowspan="1" colspan="1">73.29 &#x000b1; 3.94</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4152 (&#x02212;0.1072, 0.9375)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HFnu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.91 &#x000b1; 4.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.71 &#x000b1; 3.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.4152 (&#x02212;0.9375, 0.1072)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; standard deviation. Total power (TP), representing power at frequencies &#x02264; 0.4 Hz; very low frequency (VLF), power at frequencies &#x02264; 0.04 Hz; low frequency (LF), power between 0.04 and 0.15 Hz; high frequency (HF), power between 0.15 and 0.4 Hz; LF/HF ratio, calculated as LF divided by HF; LFnu, normalized LF power expressed as [LF/(LF + HF) &#x000d7; 100]; and HFnu, normalized HF power expressed as [HF/(LF + HF) &#x000d7; 100].</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jpm-14-01151-t003"><object-id pub-id-type="pii">jpm-14-01151-t003_Table 3</object-id><label>Table 3</label><caption><p>Efficacy of auto-titrating mandibular advancement device (AMAD) treatment on shift in autonomic dysregulation in patients with obstructive sleep apnea.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n = 15</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Baseline</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AMAD Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Ultra-short-term</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TP (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">69,783.72 &#x000b1; 5488.07</td><td align="center" valign="middle" rowspan="1" colspan="1">43,356.15 &#x000b1; 7398.55</td><td align="center" valign="middle" rowspan="1" colspan="1">4.2437 (2.8950, 5.5923)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VLF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">31,447.63 &#x000b1; 5147.10</td><td align="center" valign="middle" rowspan="1" colspan="1">19,137.63 &#x000b1; 7398.55</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4203 (1.4359, 3.4047)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">16,954.95 &#x000b1; 345.16</td><td align="center" valign="middle" rowspan="1" colspan="1">13,645.90 &#x000b1; 797.45</td><td align="center" valign="middle" rowspan="1" colspan="1">5.3855 (3.7769, 6.9942)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">5681.07 &#x000b1; 1287.25</td><td align="center" valign="middle" rowspan="1" colspan="1">5981.98 &#x000b1; 1324.00</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2304 (&#x02212;0.9809, 0.5200)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF/HF ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">3.12 &#x000b1; 0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">2.38 &#x000b1; 0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2613 (0.4423, 2.0803)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LFnu</td><td align="center" valign="middle" rowspan="1" colspan="1">75.16 &#x000b1; 4.00</td><td align="center" valign="middle" rowspan="1" colspan="1">69.80 &#x000b1; 4.42</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2691 (0.4493, 2.0890)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HFnu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.84 &#x000b1; 4.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.20 &#x000b1; 4.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.2691 (&#x02212;2.0890, &#x02212;0.4493)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Short-term</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TP (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">68,490.45 &#x000b1; 5488.07</td><td align="center" valign="middle" rowspan="1" colspan="1">41,268.15 &#x000b1; 6843.13</td><td align="center" valign="middle" rowspan="1" colspan="1">4.3896 (3.0086, 57,705)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VLF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">31,624.46 &#x000b1; 5629.82</td><td align="center" valign="middle" rowspan="1" colspan="1">22,638.98 &#x000b1; 4620.36</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7448 (0.8660, 2.6236)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">16,945.74 &#x000b1; 534.53</td><td align="center" valign="middle" rowspan="1" colspan="1">14,090.57 &#x000b1; 709.80</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5442 (3.1288, 5.9597)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">5485.34 &#x000b1; 1447.02</td><td align="center" valign="middle" rowspan="1" colspan="1">5733.05 &#x000b1; 1394.67</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1743 (&#x02212;0.9237, 0.5751)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF/HF ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">3.29 &#x000b1; 0.83</td><td align="center" valign="middle" rowspan="1" colspan="1">2.59 &#x000b1; 0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9743 (0.1832, 1.7654)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LFnu</td><td align="center" valign="middle" rowspan="1" colspan="1">75.85 &#x000b1; 4.66</td><td align="center" valign="middle" rowspan="1" colspan="1">71.40 &#x000b1; 4.71</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9481 (0.1593, 1.7370)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HFnu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.15 &#x000b1; 4.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.60 &#x000b1; 4.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.9481 (&#x02212;1.7370, &#x02212;0.1593)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.01</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; standard deviation. Total power (TP), representing power at frequencies &#x02264; 0.4 Hz; very low frequency (VLF), power at frequencies &#x02264; 0.04 Hz; low frequency (LF), power between 0.04 and 0.15 Hz; high frequency (HF), power between 0.15 and 0.4 Hz; LF/HF ratio, calculated as LF divided by HF; LFnu, normalized LF power expressed as [LF/(LF + HF) &#x000d7; 100]; and HFnu, normalized HF power expressed as [HF/(LF + HF) &#x000d7; 100].</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jpm-14-01151-t004"><object-id pub-id-type="pii">jpm-14-01151-t004_Table 4</object-id><label>Table 4</label><caption><p>Comparison of nocturnal heart rate variability between conventional mandibular advancement device (MAD) and auto-titrating mandibular advancement device (AMAD) groups in patients with mild obstructive sleep apnea (OSA).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mild OSA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conventional MAD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AMAD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Test Statistics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Ultra-short-term</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TP (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">44,111.93 &#x000b1; 8624.79</td><td align="center" valign="middle" rowspan="1" colspan="1">43,348.00 &#x000b1; 9114.64</td><td align="center" valign="middle" rowspan="1" colspan="1">0.20</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0872 (&#x02212;0.9474, 0.7730)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VLF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">20,441.30 &#x000b1; 6506.23</td><td align="center" valign="middle" rowspan="1" colspan="1">18,898.35 &#x000b1; 5102.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2505 (&#x02212;1.1131, 0.6122)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">14,663.74 &#x000b1; 872.95</td><td align="center" valign="middle" rowspan="1" colspan="1">13,900.63 &#x000b1; 874.49</td><td align="center" valign="middle" rowspan="1" colspan="1">2.09</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.8738 (&#x02212;1.7665, 0.0190)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">5641.62 &#x000b1; 1137.80</td><td align="center" valign="middle" rowspan="1" colspan="1">5929.12 &#x000b1; 1108.35</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2544 (&#x02212;0.6083, 1.1172)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF/HF ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">2.70 &#x000b1; 0.56</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41 &#x000b1; 0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4311</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5410 (&#x02212;1.4136, 0.3317)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LFnu</td><td align="center" valign="middle" rowspan="1" colspan="1">72.41 &#x000b1; 3.90</td><td align="center" valign="middle" rowspan="1" colspan="1">70.25 &#x000b1; 3.91</td><td align="center" valign="middle" rowspan="1" colspan="1">1.32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5535 (&#x02212;1.4267, 0.3197)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.21</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HFnu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.59 &#x000b1; 3.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.75 &#x000b1; 3.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5535 (&#x02212;0.3197, 1.4267)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Short-term</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TP (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">43,220.77 &#x000b1; 7432.44</td><td align="center" valign="middle" rowspan="1" colspan="1">40,994.05 &#x000b1; 8183.73</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2914 (&#x02212;1.1550, 0.5722)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VLF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">24,347.97 &#x000b1; 7145.90</td><td align="center" valign="middle" rowspan="1" colspan="1">21,784.67 &#x000b1; 4026.35</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3970 (&#x02212;1.2638, 0.4697)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">14,725.13 &#x000b1; 865.56</td><td align="center" valign="middle" rowspan="1" colspan="1">14,283.31 &#x000b1; 652.04</td><td align="center" valign="middle" rowspan="1" colspan="1">1.47</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5430 (&#x02212;1.4158, 0.3297)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">5221.29 &#x000b1; 1144.04</td><td align="center" valign="middle" rowspan="1" colspan="1">5630.11 &#x000b1; 996.72</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3695 (&#x02212;0.4963, 1.2354)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF/HF ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">2.94 &#x000b1; 0.60</td><td align="center" valign="middle" rowspan="1" colspan="1">2.60 &#x000b1; 0.43</td><td align="center" valign="middle" rowspan="1" colspan="1">1.66</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.6009 (&#x02212;1.4765, 0.2746)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LFnu</td><td align="center" valign="middle" rowspan="1" colspan="1">74.04 &#x000b1; 3.99</td><td align="center" valign="middle" rowspan="1" colspan="1">71.87 &#x000b1; 3.51</td><td align="center" valign="middle" rowspan="1" colspan="1">1.42</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5606 (&#x02212;1.4341, 0.3130)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HFnu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.96 &#x000b1; 3.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.13 &#x000b1; 3.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5606 (&#x02212;0.3130, 1.4341)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; standard deviation. Total power (TP), representing power at frequencies &#x02264; 0.4 Hz; very low frequency (VLF), power at frequencies &#x02264; 0.04 Hz; low frequency (LF), power between 0.04 and 0.15 Hz; high frequency (HF), power between 0.15 and 0.4 Hz; LF/HF ratio, calculated as LF divided by HF; LFnu, normalized LF power expressed as [LF/(LF + HF) &#x000d7; 100]; and HFnu, normalized HF power expressed as [HF/(LF + HF) &#x000d7; 100]. Continuous variables were assessed using Welch&#x02019;s <italic toggle="yes">t</italic> test, along with corresponding <italic toggle="yes">t</italic> statistic and degrees of freedom (df).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jpm-14-01151-t005"><object-id pub-id-type="pii">jpm-14-01151-t005_Table 5</object-id><label>Table 5</label><caption><p>Comparison of nocturnal heart rate variability between conventional mandibular advancement device (MAD) and auto-titrating mandibular advancement device (AMAD) groups in patients with moderate obstructive sleep apnea (OSA).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Moderate OSA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conventional MAD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AMAD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Test Statistics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Ultra-short-term</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TP (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">43,954.48 &#x000b1; 11,698.87</td><td align="center" valign="middle" rowspan="1" colspan="1">43,365.47 &#x000b1; 5549.79</td><td align="center" valign="middle" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0872 (&#x02212;0.9474, 0.7730)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VLF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">32,341.30 &#x000b1; 34,096.28</td><td align="center" valign="middle" rowspan="1" colspan="1">19,411.10 &#x000b1; 5325.58</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2505 (&#x02212;1.1131, 0.6122)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">15,829.38 &#x000b1; 994.09</td><td align="center" valign="middle" rowspan="1" colspan="1">13,354.77 &#x000b1; 637.35</td><td align="center" valign="middle" rowspan="1" colspan="1">6.25</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.8738 (&#x02212;1.7665, 0.0190)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">6542.91 &#x000b1; 1209.49</td><td align="center" valign="middle" rowspan="1" colspan="1">6042.38 &#x000b1; 1627.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2544 (&#x02212;0.6083, 1.1172)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF/HF ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">2.49 &#x000b1; 0.47</td><td align="center" valign="middle" rowspan="1" colspan="1">2.34 &#x000b1; 0.60</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5410 (&#x02212;1.4136, 0.3317)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LFnu</td><td align="center" valign="middle" rowspan="1" colspan="1">70.95 &#x000b1; 3.60</td><td align="center" valign="middle" rowspan="1" colspan="1">69.29 &#x000b1; 5.23</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5535 (&#x02212;1.4267, 0.3197)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.49</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HFnu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.05 &#x000b1; 3.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.71 &#x000b1; 5.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5535 (&#x02212;0.3197, 1.4267)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.49</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Short-term</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TP (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">42,184.17 &#x000b1; 10,237.44</td><td align="center" valign="middle" rowspan="1" colspan="1">41,581.40 &#x000b1; 555.48</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2914 (&#x02212;1.1550, 0.5722)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VLF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">23,567.59 &#x000b1; 8612.04</td><td align="center" valign="middle" rowspan="1" colspan="1">23,615.34 &#x000b1; 5367.75</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3970 (&#x02212;1.2638, 0.4697)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">15,734.57 &#x000b1; 1043.54</td><td align="center" valign="middle" rowspan="1" colspan="1">13,870.29 &#x000b1; 757.24</td><td align="center" valign="middle" rowspan="1" colspan="1">4.27</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5430 (&#x02212;1.4158, 0.3297)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">6254.22 &#x000b1; 1237.50</td><td align="center" valign="middle" rowspan="1" colspan="1">5850.70 &#x000b1; 1830.10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3695 (&#x02212;0.4963, 1.2354)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.62</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LF/HF ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">2.60 &#x000b1; 0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">2.57 &#x000b1; 0.77</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.6009 (&#x02212;1.4765, 0.2746)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LFnu</td><td align="center" valign="middle" rowspan="1" colspan="1">71.79 &#x000b1; 3.56</td><td align="center" valign="middle" rowspan="1" colspan="1">70.88 &#x000b1; 6.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5606 (&#x02212;1.4341, 0.3130)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HFnu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.21 &#x000b1; 3.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.12 &#x000b1; 6.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5606 (&#x02212;0.3130, 1.4341)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.73</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; standard deviation. Total power (TP), representing power at frequencies &#x02264; 0.4 Hz; very low frequency (VLF), power at frequencies &#x02264; 0.04 Hz; low frequency (LF), power between 0.04 and 0.15 Hz; high frequency (HF), power between 0.15 and 0.4 Hz; LF/HF ratio, calculated as LF divided by HF; LFnu, normalized LF power expressed as [LF/(LF + HF) &#x000d7; 100]; and HFnu, normalized HF power expressed as [HF/(LF + HF) &#x000d7; 100]. Continuous variables were assessed using Welch&#x02019;s <italic toggle="yes">t</italic> test, along with corresponding t statistic and degrees of freedom (df).</p></fn></table-wrap-foot></table-wrap></floats-group></article>